Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGCG on Frailty and Inflammation in Older Cancer Survivors
NCT06068543Phase 2Suspended
- Sponsor
- University of Rochester
- Start
- Oct 2024
- Primary completion
- Jan 2030
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epigallocatechin gallate in frailty syndrome, inflammation, sponsored by University of Rochester. Started Oct 2024; status: suspended.
02
Drugs
epigallocatechin gallate
03
Conditions
frailty syndromeinflammation
Beyond the preview
Go deeper on NCT06068543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068543.